Comparison of the rapid pro-apoptotic effect of trans-β-nitrostyrenes with delayed apoptosis induced by the standard agent 5-fluorouracil in colon cancer cells

Apoptosis

Volumn 12, Issue 1, 2007, Pages 235-246

  Werner, Jens Martin ^a   Eger, Kurt ^b   Jürgen Steinfelder, Hans ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

5 Fluorouracil; Caspase 3 activation; DNA fragmentation; Drug induced apoptosis; LoVo adenocarcinoma cells; Trans nitrostyrene

Indexed keywords

2 BROMO BETA NITROSTYRENE; 2 METHYL BETA NITROSTYRENE; 2,4,6 TRIAMINOPYRIMIDINE NITROSTYRENE ADDUCT; CASPASE 3; CASPASE 8; CISPLATIN; DNA FRAGMENT; FLUOROURACIL; NITROSTYRENE; NITROSTYRENE ASCORBIC ACID ADDUCT; NITROSTYRENE CYSTEINE ADDUCT; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; STYRENE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HCT116; CELL STRAIN HT29; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ASSAY; HUMAN; HUMAN CELL; MICROSCOPY; PRIORITY JOURNAL; RESPONSE TIME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; COLONIC NEOPLASMS; DNA FRAGMENTATION; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FLUOROURACIL; HUMANS; STYRENES;

EID: 33845729344     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-006-0530-x     Document Type: Article

References (71)

1. Stewart BW, Kleihues P (eds) (2003) World cancer report. IARC Press, Lyon, France
2. Van Cutsem E, Dicato M, Wils J et al (2002) Adjuvant treatment of colorectal cancer (current expert opinion derived from the third international conference: perspectives in colorectal cancer, Dublin, 2001). Eur J Cancer 38:1429-1436
3. Goker E, Gorlick R, Bertino JR (1998) Resistance mechanisms to antimetabolites. In: Pinedo HM, Giaccone G (eds) Drug resistance in the treatment of cancer. Cambridge University Press, Cambridge, MA, USA, pp 1-13
4. Yoshimatsu K, Kato H, Ishibashi K et al (2003) Second-line chemotherapy with low-dose CPT-11 and cisplatin for colorectal cancer resistant to 5-FU-based chemotherapy. Cancer Chemother Pharmacol 52(6):465-468
5. Cazin JL, Gosselin P, Cappelaere P et al (1992) Drug resistance in oncology: from concepts to applications editorial. J Cancer Res Clin Oncol 119:76-86
6. Gorlick R, Banerjee D (2002) Fluoropyrimidine resistance in colon cancer. Expert Rev Anticancer Ther 2:409-416
7. Violette S, Poulain L, Dussaulx E et al (2002) Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer 98:498-504
8. Kuranaga N, Shinomiya N, Mochizuki H (2001) Long-term cultivation of colorectal carcinoma cells with anti-cancer drugs induces drug resistance and telomere elongation: an in vitro study. BMC Cancer 1:10
9. Iqbal S, Lenz HJ (2001) Determinants of prognosis and response to therapy in colorectal cancer. Curr Oncol Rep 3:102-108
10. Rougier PH, Paillot B, LaPlanche A (1997) 5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer. Eur J Cancer 33:1789-1793
11. Pazdur R (1998) New agents for colorectal cancers: Oral fluorinated pyrimidines and oxaliplatin. In: Educational book, ASCO, 34th annual meeting, May 16-19. ASCO, Alexandria, Los Angeles, pp 301-310
12. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E (2002) Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1:227-235
13. Arango D, Wilson AJ, Shi Q et al (2004) Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 91:1931-1946
14. Guichard S, Cussac D, Hennebelle I, Bugat R, Canal P (1997) Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int J Cancer 73:729-734
15. Xu JM, Azzariti A, Tommasi S et al (2002) Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance. Clin Colorectal Cancer 2:182-188
16. Schmidt WM, Kalipciyan M, Dornstauder E et al (2004) Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profiling. Int J Cancer 112:200-212
17. Lowe SW, Lin AW (2000) Apoptosis in cancer. Carcinogenesis 21:485-495
18. Johnstone RW, Ruefli AA, Lowe SW (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108:153-164
19. Arends MJ, Wyllie AH (1991) Apoptosis: mechanisms and roles in pathology. Int Rev Exp Path 32:223-354
20. Cho SG, Choi EJ (2002) Apoptotic signalling pathways: caspases and stress-activated protein kinases. J Biochem Mol Biol. 35:24-27
21. Chang HY, Yang X (2000) Proteases for cell suicide, functions and regulation of caspases. Microbiol Mol Biol Rev 64:821-846
22. Fuentes-Prior P, Salvesen GS (2004) The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem J 384:201-232
23. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, Peter ME (1998) Apoptosis signalling by death receptors. Eur J Biochem 254:439-459
24. Bratton SB, MacFarlane M, Cain K, Cohen GM (2000) Protein complexes activate distinct caspases cascades in death receptor and stress-induced apoptosis. Exp Cell Res 256:27-33
25. Debatin KM, Krammer PH (2004) Death receptors in chemotherapy and cancer. Oncogene 23:2950-2966
26. Desagher S, Osen-Sand A, Nichols A et al (1999) Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol 144:891-901
27. Hengartner MO (2000) The biochemistry of apoptosis. Nature 407:770-776
28. Green DR, Kroemer G (2004) The pathophysiology of mitochondrial cell death. Science 305:626-629
29. Jänicke RU, Sprengart ML, Wati MR, Porter AG (1998) Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273:9357-9360
30. Alonso A, Sasin J, Bottini N et al (2004) Protein tyrosine phosphatases in the human genome. Cell 117:699-711
31. Kato Y, Fusetani N, Matsunaga S, Hashimoto K (1988) Calyculins, potent antitumour metabolites from the marine sponge Discodermia calyx: biological activities. Drugs Exp Clin Res 14:723-728
32. Kiguchi K, Glesne D, Chubb CH, Fujiki H, Huberman E (1994) Differential induction of apoptosis in human breast tumor cells by okadaic acid and related inhibitors of protein phosphatases 1 and 2A. Cell Growth Differ 5:995-1004
33. von Zezschwitz C, Vorwerk H, Tergau F, Steinfelder HJ (1997) Apoptosis induction by inhibitors of Ser/Thr phosphatases 1 and 2A is associated with transglutaminase activation in two different human epithelial tumour lines. FEBS Lett 413:147-151
34. Chen YH, Chen JC, Yin SC et al (2002) Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cell lines. Int J Cancer 100:158
35. Deng X, Ito T, Carr B, Mumby M, May WS (1998) Reversible phosphorylation of Bcl-2 following interleukin 3 or bryostatin 1 is mediated by direct interaction with protein phosphatase 2A. J Biol Chem 273:34157
36. Haldar S, Jena N, Croce CM (1995) Inactivation of bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92:4507
37. Ruvolo PP, Deng XM, Ito T, Carr BK, May WS (1999) Ceramide induces Bcl-2 dephosphorylation via a mechanism involving mitochondrial PP2A. J Biol Chem 274:20296
38. Santoro MF, Annand RR, Robertson MM et al (1998) Regulation of protein phosphatase 2A activity by caspase-3 during apoptosis. J Biol Chem 273:13119-13128
39. Li YM, Casida JE (1992) Cantharidin-binding protein: identification as protein phosphatase 2A. Proc Natl Acad Sci USA 89:11867-11870
40. Hart ME, Chamberlin AR, Walkom C, Sakoff JA, McCluskey A (2004) Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity. Bioorg Med Chem Lett. 14:1969-1973
41. Peng F, Wei YQ, Tian L et al (2002) Induction of apoptosis by norcantharidin in human colorectal carcinoma cell lines: involvement of the CD95 receptor/ligand. J Cancer Res Clin Oncol 128:223-230
42. McCluskey A, Ackland SP, Gardiner E, Walkom CC, Sakoff JA (2001) The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design? Anticancer Drug Des 16:291-303
43. Sakoff JA, Ackland SP, Baldwin ML, Keane MA, McCluskey A (2002) Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues. Invest New Drugs 20:1-11
44. Park J, Pei D (2004) Trans-B-Nitrostyrene Derivates as slow-binding inhibitors of protein tyrosine phosphatases. Biochemistry 43:15014-15021
45. Fathi AR, Krautheim A, Kaap S, Eger K, Steinfelder HJ (2000) Michael adducts of ascorbic acid as inhibitors of protein phosphatase 2A and inducers of apoptosis. Bioorg Med Chem Lett 10:1605-1608
46. Kaap S, Quentin I, Tamiru D, Shaheen M, Eger K, Steinfelder HJ (2003) Structure activity of the pro-apoptotic, anti-tumour effect of nitrostyrene adducts and related compounds. Biochem Pharmacol 65:603-610
47. Drewinko B, Romsdahl MM, Yang LY, Ahearn MJ, Drujillo JM (1976) Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line. Cancer Res 36:467-475
48. Steinfelder HJ, Hauser P, Nakayama Y et al (1988) Thyrotropin H-releasing hormone regulation of human TSH· expression: role of pituitary-specific transcription factor (Pit/GHF-1) and potential interaction with a thyroid hormone-inhibitory element. Proc Acad Sci USA 88:3130-3133
49. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
50. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
51. + channel-blocking insulin secretagogues. Biochem Pharmacol 67:1733-1741
52. Arends MJ, Morris RG, Wyllie AH (1990) Apoptosis. The role of the endonuclease. Am J Pathol 136:593-598
53. GLOBOCAN 2000 (2001) cancer incidence, mortality and prevalence worldwide, version 1.0. IARC CancerBase no. 5. Lyon. IARC Press, France
54. Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Multicenter international study of Oxaliplatin/5-Fluorouracil/Leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351
55. Twelves C, Wong A, Nowacki MP et al (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696-2704
56. Milhazes N, Calheiros R, Marques MP et al (2006) Beta-nitrostyrene derivatives as potential antibacterial agents: a structure-property-activity relationship study. Bioorg Med Chem. 14:4078-4088
57. Tokunaga E, Oda S, Fukushima M, Maehara Y, Sugimachi K (2000) Differential growth inhibition by 5-fluorouracil in human colorectal carcinoma cell lines. Eur J Cancer 36:1998-2006
58. Chen XX, Lai MD, Zhang YL, Huang Q (2002) Less cytotoxity to combination of 5-fluorouracil and cisplatin than 5-fluorouracil alone in human colon cancer cell lines. World J Gastroenterol 8:841-846
59. Honkanen RE (1993) Cantharidin, another natural toxin that inhibits the activity of serin/threonine protein phosphatases types 1 and 2A. FEBS Lett 330:283-286
60. 3H]cantharidin binding site in relation to cytotoxicity. J Pharmacol Exp Ther 280:1152-1158
61. Sieder S, Richter E, Becker K, Heins R, Steinfelder HJ (1999) Doxorubicin-resistant LoVo adenocarcinoma cells display resistance to apoptosis induction by some but not all inhibitors of ser/thr phosphatases 1 and 2A. Toxicology 134:109-115
62. Adachi Y, Taketani S, Oyaizu H, Ikebukuro K, Tokunaga R, Ikehara S (1999) Apoptosis of colorectal adenocarcinoma induced by 5-FU and/or IFN-gamma through caspase 3 and caspase 8. Int J Oncol 15:1191-1196
63. Backus HH, Wouters D, Ferreira CG et al (2003) Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines. Eur J Cancer 39:1310-1317
64. Wang K, Yian XM, Chao DT, Milliman CL, Korsmeyer SJ (1996) BID: A novel BH3 domain only death agonist. Genes Dev 10:2859-2869
65. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD (1997) The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275:1132-1136
66. Huh JE, Kang KS, Chae C et al (2004) Roles of p38 and JNK mitogen-activated protein kinase pathways during cantharidin-induced apoptosis in U937 cells. Biochem Pharmacol 67:1811-1818
67. 2+ dependent phosphatase activity. Biochem Pharmacol 67:919-926
68. Guo YL, Baysal K, Kang B, Yang LJ, Williamson JR (1998) Correlation between sustained c-Jun N-terminal protein kinase activation and apoptosis induced by tumor necrosis factor-a in rat mesangial cells. J Biol Chem 273:4027-4034
69. Schroeter H, Boyd CS, Ahmed R et al (2003) c-Jun N-terminal kinase (JNK)-mediated modulation of brain mitochondria function: newtarget proteins for JNK signalling in mitochondrion-dependent apoptosis. Biochem J 372:359-369
70. Kitada S, Zapata JK, Andreeff M, Reed JC (2000) Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukaemia. Blood 96:393-397
71. Arnould S, Hennebelle I, Canal P, Bugat R, Guichard S (2003) Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 39:112-119